Artificial Intelligence for Schizophrenia Biotyping: Priority-Based Policy Considerations

Artificial intelligence applied to large, multimodal schizophrenia datasets aims to identify reproducible subgroups of patients distinguished by their underlying biology, rather than by symptoms alone, a practice commonly termed ‘biotyping’. Biotyping may one-day sharpen diagnosis, individualise treatment and improve prognosis. However, it also carries distinctive ethical and practical risks. Deployed in diagnostic settings, such tools may introduce or entrench algorithmic bias, threaten equity, and obscure communication between clinicians and patients. This brief argues that current policy frameworks would benefit from scrutiny directed specifically at schizophrenia, both to protect patient-care standards and to enable responsible clinical adoption. It sets out three policy pathways tailored to the disorder, which are offered as priorities, but not as an exhaustive treatment of the field.